Prospective multicentre study of chemotherapeutic regimen containing pirarubicin on the treatment of relapsed or refractory acute myeloid leukemia in adults.
- Author:
Feng CHEN
1
;
Jingxia WANG
;
Ming HOU
;
Hongguo ZHAO
;
Enqin YANG
;
Xuehong RAN
;
Minglin WANG
;
Wenzheng YU
;
Ruirong XU
;
Zhencheng WANG
;
Kehong BI
;
Xin WANG
;
Guoqiang LIU
;
Sheng YANG
;
Jin FAN
;
Lingling WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antineoplastic Combined Chemotherapy Protocols; administration & dosage; therapeutic use; Dactinomycin; administration & dosage; Doxorubicin; administration & dosage; analogs & derivatives; Etoposide; administration & dosage; Granulocyte Colony-Stimulating Factor; administration & dosage; Humans; Leukemia, Myeloid, Acute; drug therapy; Methotrexate; administration & dosage; Prospective Studies; Recurrence; Remission Induction
- From: Chinese Journal of Hematology 2014;35(5):388-392
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy and toxicity of the chemotherapeutic regimen containing pirarubicin and mitoxantrone on the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults.
METHODSIn this open prospective multicentre study, we randomly assigned patients with relapsed or refractory AML to receive TAE regimen (pirarubicin+cytarabine+etoposide) versus MAE regimen (mitoxantrone + cytarabine + etoposide). The efficacy and toxicity were compared between the two groups.
RESULTS56 patients entered this clinical trial. The complete remission (CR) rate on TAE arm was 79.0% versus 55.6% on MAE arm with the overall response (OR) rates of 86.8% versus 88.9%, respectively. The CR was higher on TAE arm (P=0.035) but with no significant difference between the two groups regarding the overall response (OR) rate. The regimens were well tolerated in both groups. Hematologic and non-hematologic toxicity were similar except relatively lower the mean dosage of G-CSF, red blood cells and platelets transfusion on TAE arm. No significant differences were seen between the two groups regarding the overall survival and relapse free survival rates.
CONCLUSIONTAE regimen might be an effective salvage therapy in patients with relapsed or refractory AML.
